Digital
October 22nd - 23rd, 2020

3rd Annual MarketsandMarkets Real-World Data, Life Sciences Analytics and Market Access Virtual Conference ( Time Zone - EASTERN STANDARD TIME (EST)

MarketsandMarkets is proud to announce the 3rd Annual Real-World Data, Life Sciences Analytics and Market Access – Virtual Conference to be held on October 22nd -23rd, 2020.

While the 2nd annual Congress had discussions on accelerating the adoption of Real-world Evidence within the industry while understanding the capabilities of newer technologies for evidence generation, the 3rd Annual will focus on how the insights derived from real world data, as well as acknowledgment of the effect the insights can have on improving decision making and patient consideration both internally and by regulators, doctors, and payers.

Our aim for the 3rd Annual Real-World Data, Life Sciences Analytics and Market Access – Virtual Conference is to unite all stakeholders in a virtual room during these remarkable times to see how to use conventional informational indexes and layer that in with innovative analytical techniques and new working models.

The virtual conference will also hold discussion on the impact due to COVID-19 in RWD space- Identifying and overcoming those challenges efficiently

WHAT TO EXPECT

Key Highlights

  • Progression on uses of Real-World Data across the ecosystem
  • Global regulatory perspective on Real-World Evidence Guidance- FDA & EMA
  • Applications of Artificial Intelligence & Blockchain for Real-World Data Analysis
  • Market Access and Pricing
  • COVID-19 impact- Identifying and overcoming challenges in Real-World Evidence space

Who Should Attend?

From pharmaceutical and Biopharmaceutical companies-

Chief executives, VP’s, Directors, Global heads, Heads, Leaders, Senior Managers, Researcher, Analysts, Investigators, Scientists, Bio-Statisticians, Epidemiologist, within the following departments

  • Real-World Evidence
  • Health Economics & Outcomes Research
  • Patient Access
  • Value Access
  • Clinical Operations
  • Clinical Development
  • Center for Observational and Real-World Evidence  

 

Why Attend?

  • Understand the impact of innovative real-world evidence partnerships for better data
  • To explore the capabilities of using Artificial Intelligence & Machine Learning for better Data Analysis
  • Learn about global regulatory perspective on Real-World Evidence Guidance
  • Learn about best practices for the commercial structure of drugs, from development to market access strategy
  • Opportunity to network and exchange scientific knowledge with expert speakers from leading manufacturers, global regulators, and solution providers

CONFERENCE AGENDA
NEW FORMS OF REAL-WORLD DATA
BREAKTHROUGH TO EXCELLENT DATA EVALUATION
CONFERENCE SPEAKERS
Speakers
Charles Makin
Charles Makin
Global Head, Real World Evidence Strategy , Biogen
Nneka Onwudiwe
Nneka Onwudiwe
Former PRO/PE Regulatory Review Officer, FOOD AND DRUG ADMINISTRATION
Vic Spain
Vic Spain
Senior Real World Data Scientist , Genentech
David Miller
David Miller
Executive Director, Head of RWE- Patient Safety, Sarepta Therapeutics, USA
Nirosha Lederer
Nirosha Lederer
Managing Associate, Real World Evidence, Duke Margolis Center for Health Policy, Duke University
Alexander Cole
Alexander Cole
Executive Director, Global Head Epidemiology, Alexion Pharmaceuticals
Raymond Frost
Raymond Frost
Vice President, Market Access & Health Policy, Melinta
Eliza Kruger
Eliza Kruger
Associate Director, Global HEOR, Ultragenyx Pharmaceuticals
SPONSORS
Sponsors & Exhibitors
example-image

Adelphi Real World

example-image

Picnic Health

example-image

OPEN Health

example-image

Premier Inc.

Speaking Partner
example-image

QIAGEN

example-image

Verantos

example-image

Syneos Health

example-image

Molecular Connections

example-image

Kantar

example-image

Savana

example-image

Aetion

example-image

RTI Health Solutions

example-image

LynxCare

PAST EVENT GALLERY